Evidence map›Paper›PMID 40435586›Full record

ArticleSchizophrenia research2025

Negative symptoms, cognition, and community functioning in early psychosis.

Julia Blotner, Rachel Hechinger, Martha E Shenton, Michael J Coleman, Dost Öngür, Kathryn E Lewandowski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Schizophrenia research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Julia BlotnerSchizophrenia and Bipolar Disorder Program, McLean Hospital, 115 Mill Street, Belmont, MA, USA.
Rachel HechingerSchizophrenia and Bipolar Disorder Program, McLean Hospital, 115 Mill Street, Belmont, MA, USA.
Martha E ShentonPsychiatry Neuroimaging Laboratory, Brigham and Women's Hospital, 399 Revolution Drive Suite 1155, Somerville, MA, USA; Department of Psychiatry, Harvard Medical School, 401 Park Drive, Boston, MA, USA; Department of Radiology, Harvard Medical School, 25 Shattuck Street, Boston, MA, USA.
Michael J ColemanPsychiatry Neuroimaging Laboratory, Brigham and Women's Hospital, 399 Revolution Drive Suite 1155, Somerville, MA, USA.
Dost ÖngürSchizophrenia and Bipolar Disorder Program, McLean Hospital, 115 Mill Street, Belmont, MA, USA; Department of Psychiatry, Harvard Medical School, 401 Park Drive, Boston, MA, USA.
Kathryn E LewandowskiSchizophrenia and Bipolar Disorder Program, McLean Hospital, 115 Mill Street, Belmont, MA, USA; Department of Psychiatry, Harvard Medical School, 401 Park Drive, Boston, MA, USA. Electronic address: klewandowski@mclean.harvard.edu.

Funding

Randomized controlled trial of enhanced coordinated specialty care (CSC 2.0)P50MH115846 · NIMH · MCLEAN HOSPITAL · PI Dost Ongur · 2019 to 2026
$16.9M
Human Connectome Project for Early PsychosisU01MH109977 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI BREIER, ALAN, SHENTON, MARTHA E. · 2016 to 2020
$5.5M
Neuroprogression across the Psychosis Spectrum in the Early Course of IllnessR01MH117012 · NIMH · MCLEAN HOSPITAL · PI LEWANDOWSKI, KATHRYN EVE · 2019 to 2023
$2.4M
NIMH NIH HHS P50 MH115846NIMH NIH HHS R01 MH117012NIMH NIH HHS U01 MH109977
6 · The paper itself

Abstract

introductionNegative symptoms are associated with poorer cognitive functioning in psychosis, and both negative symptoms and cognition are associated with poorer community functioning, even in the early course of illness. Current conceptualizations of negative symptoms in psychosis have identified separate subdomains, not all of which may be affected in every patient; however, few studies have examined associations between specific negative symptom subdomains and cognition and functioning in early psychosis.

methodsParticipants with schizophrenia spectrum disorders (SSD; n = 26) or mood disorders with psychosis (MDP; n = 41) within the first 6.5 years of illness were assessed at two timepoints on negative symptoms (BNSS and CAINS), cognition, and functioning. Group comparisons and correlations among measures were conducted, and linear regression predicting functioning at follow-up by baseline negative symptoms and cognition were run.

resultsGroups did not differ on negative symptoms or cognition at either timepoint. The SSD group had more impaired functioning at both timepoints. BNSS and CAINS total scores and several subscales correlated with cognition at both timepoints transdiagnostically. At baseline, BNSS Anhedonia, Asociality, and total score and CAINS Motivation and Pleasure and total score significantly predicted MIRECC GAF symptoms at follow-up and BNSS Asociality, Avolition, and BNSS and CAINS total scores predicted MIRECC GAF social functioning at follow-up. Cognition did not predict functioning at follow-up.

conclusionBaseline negative symptoms of amotivation and anhedonia, but not cognition, predicted measures of functioning at follow-up. These findings suggest that interventions targeting motivation and hedonic capacity early in treatment may improve future functioning.

Indexed as

AnhedoniaCognitive DysfunctionMood DisordersPsychosocial FunctioningPsychotic DisordersSchizophreniaAdolescentAdultFemaleFollow-Up StudiesHumansMaleYoung AdultCommunity functioningEarly psychosisNegative symptomsNIH toolbox cognition

Identifiers

PMID40435586
PMCPMC12183596

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.